Madorra develops a nonhormonal, noninvasive medical device to treat moderate to severe vulvovaginal atrophy, a condition that causes vaginal dryness in post-menopausal individuals and breast cancer survivors. By providing an alternative to pharmaceutical treatments, Madorra empowers users to manage their vaginal health effectively.
Funding
Funding not disclosed
5LFounders
Product
Problem
Vulvovaginal atrophy (VVA), characterized by vaginal dryness, affects many post-menopausal individuals and breast cancer survivors, significantly impacting their quality of life. Current pharmaceutical treatments may not be desirable or appropriate for all individuals.
Solution
Madorra is developing a non-hormonal, non-invasive medical device designed to treat moderate to severe VVA. The device offers an alternative to pharmaceutical interventions, empowering individuals to proactively manage their vaginal health. By providing a user-friendly solution, Madorra aims to improve the quality of life for individuals experiencing vaginal dryness due to menopause or cancer treatments. The device is intended for home use and aims to restore vaginal moisture and elasticity through regular application.
Target Audience
The primary target audience includes post-menopausal individuals and breast cancer survivors experiencing moderate to severe vulvovaginal atrophy.
Features
- Non-hormonal and non-invasive treatment for vulvovaginal atrophy
- Designed for home use
- Aims to restore vaginal moisture and elasticity
- Intended for post-menopausal individuals and breast cancer survivors